Saint Maur Des Fosses

Researchers are evaluating the real-world effectiveness of deucravacitinib in adults diagnosed with moderate-to-severe plaque psoriasis. This observational study aims to understand how this treatment works outside of controlled clinical trials, focusing on health outcomes important to patients and doctors. It is sponsored by Bristol-Myers Squibb and conducted in France. Participants in this study have started treatment with deucravacitinib as prescribed by their doctors. The study observes these patients over time without altering their treatment plans. There are no placebo or comparison groups since this is an observational study that follows patients initiating deucravacitinib treatment. During the study, doctors will assess skin condition using the Physicians Global Assessment and measure quality of life with the Dermatology Life Quality Index at baseline and several points up to 24 months. Patients will also report symptoms like itch, skin pain, and fatigue using visual scales. Researchers will track how long patients remain on treatment and reasons for stopping. The study involves regular follow-ups at months 1, 4, 12, 18 optional, and 24 to gather this information.

Researchers are evaluating the safety and performance of hyaluronic acid-based dermal fillers designed to enhance facial features such as the lips, perioral lines, nasolabial folds, cheeks, and infraorbital hollows. This post-market interventional study aims to understand how long the effects of these products last under real-life conditions in adults aged 18 years or older. Participants may receive aesthetic treatments based on their preferences and the healthcare professionals agreement. The facial injections use hyaluronic acid-based dermal fillers with COLD-X17 technology by Symatese. Follow-up visits occur every 6 months after the initial injection, lasting up to 24 months. Retreatment is optional and may be performed at the 12-month or 18-month visits if the treated areas have returned to their pre-injection state. During each visit, investigators assess safety and performance through clinical examinations, while participants evaluate their aesthetic improvement compared to before treatment. The level of pain experienced during the initial injection is recorded. Researchers measure outcomes such as the number of patients returning to baseline appearance, injection site reactions, adverse device effects, and aesthetic improvements using validated scales. The study monitors participants over two years to gather comprehensive safety and effectiveness data.

This research aims to describe how patients aged 18 years or older with moderate to severe atopic dermatitis AD are managed with systemic therapy. It focuses on patients eligible for or currently receiving systemic treatments, following their care under real-world conditions. The study involves French dermatologists experienced in AD management, whether practicing in hospitals or private offices. Treatment decisions are made independently by the physicians and not influenced by the study enrollment. Participants will receive systemic treatments for AD prescribed by their doctors as part of routine care, with no investigational drugs involved. Information will be collected during regular visits according to usual clinical practice. The study will follow patients for one year, tracking their treatments and management without altering standard care. During the year, patients will be assessed at baseline, 6 months, and 12 months. Researchers will collect data on previous and current treatments, treatment adherence, changes in disease severity, itch, sleep disturbance, skin pain, quality of life, psychological health, work absences, and hospitalizations related to AD. This comprehensive follow-up aims to better understand how systemic therapies are used and their impact on patients in everyday clinical settings.

Researchers are studying pertussis, also known as whooping cough, focusing on how the bacteria Bordetella pertussis behaves and how the immune system responds in children up to 15 years old. This research aims to understand why the disease varies in severity, especially its most severe form in infants, and to identify biomarkers that could predict disease severity. The study also considers the impact of current vaccines and bacterial evolution on the disease and vaccine effectiveness. The study involves collecting clinical data and biological samples, including deep nasal swabs and blood samples, from children suspected of having pertussis. Researchers will use advanced techniques to analyze the gene expression of B. pertussis strains and study the immune responses in the respiratory system and blood. This includes transcriptomic analysis of bacterial genes using a special gene panel and immune cell profiling over a three-year period. Participants will provide samples such as nasopharyngeal swabs and blood for analysis. Researchers will measure bacterial gene expression, plasma cytokine and chemokine levels, and immune cell types using flow cytometry. The study will monitor these factors over time to explore links between bacterial behavior and immune responses according to disease severity. The total observation period for outcome measures is three years, during which the study will track infection characteristics and immune signatures in children with pertussis.

The trial investigates the impact of different antibiotic treatments on the digestive tract colonization by extended-spectrum beta-lactamase-producing Enterobacteriaceae E-ESBL in children with febrile urinary tract infections UTIs. E-ESBL bacteria are a significant public health concern due to their resistance to many antibiotics. This research compares the emergence of E-ESBL strains in stools following treatment with either intravenous amikacin or other recommended antibiotics like ceftriaxone or cefixime in young children. Participants receive treatment for febrile UTIs with either amikacin given intravenously or with usual antibiotics such as intravenous or intramuscular ceftriaxone or oral cefixime. Before starting antibiotics, an anorectal swab is taken to check for E-ESBL colonization. A follow-up swab is performed three to four days after starting treatment to assess changes in bacterial presence. Children are monitored for the presence and type of E-ESBL bacteria in their stools four days after treatment begins. Researchers also track antibiotic resistance patterns, fever resolution, side effects related to antibiotic use, and the rate of UTI relapse over one and a half months. Participation involves stool sampling and clinical evaluations during the treatment period, with the study expected to complete by mid-2026.